The International Myeloma Working Group (IMWG) has published dozens of research studies and treatment guidelines on multiple myeloma and its related disorders. The following are a sample of the International Myeloma Working Group’s ranging publication topics:

  • Genetic predisposition for chemotherapy-induced neuropathy in multiple myeloma
  • Gene signature combinations improve prognostic stratification of multiple myeloma patients
  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study
  • Combining Fluorescent In Situ Hybridization (iFISH) data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group (IMWG) collaborative project

From doctors to patients, the goal of these publications is to help anyone better understand aspects of myeloma. The information provided in the International Myeloma Working Group’s publications seeks to help guide patients and their doctors to treating myeloma in the most effective way for every individual case.




This IMWG consensus provides recommendations on the use of 18fluorodeoxyglucose (18F-FDG) PET/CT in myeloma patients and other plasma cell disorders. from The Lancet Oncology, April 2017





This IMWG overview reviews possible treatment-related, myeloma risk factors and practical recommendations to assist physicians. from the Annals of Oncology, February 2017





In this study, the IMWG investigated the integration of proven prognostic signatures for improved patient risk stratification.





The IMWG presents new diagnostic criteria for multiple myeloma along with definitions of related plasma cell proliferative disorders. from Lancet Oncol. 2016 Aug





The IMWG consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics and several cytogenetic abnormalities.


Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.